Brown Brothers Harriman & Co’s Myriad Genetics MYGN Stock Holding History

Brown Brothers Harriman & Co’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-47,222	Closed	-$934K	–	1195
2020 Q4	$934K	Hold	47,222	–	–	0.01%	225
2020 Q3	$616K	Hold	47,222	–	–	﹤0.01%	246
2020 Q2	$535K	Hold	47,222	–	–	﹤0.01%	258
2020 Q1	$676K	Hold	47,222	–	–	0.01%	221
2019 Q4	$1.29M	Hold	47,222	–	–	0.01%	222
2019 Q3	$1.35M	Buy	+47,222	New	+$1.38M	0.01%	199
2015 Q1	–	Sell	-800	Closed	-$27K	–	814
2014 Q4	$27K	Hold	800	–	–	﹤0.01%	593
2014 Q3	$31K	Hold	800	–	–	﹤0.01%	584
2014 Q2	$31K	Buy	+800	New	+$29.8K	﹤0.01%	569

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Brown Brothers Harriman & Co's MYGN Position: Q1 2021 in Review

Brown Brothers Harriman & Co sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 47,222 shares — an estimated $934K sold.

Brown Brothers Harriman & Co first reported a position in MYGN in Q2 2014 and held it in 9 quarters. The position peaked at $1.35M in Q3 2019. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

Brown Brothers Harriman & Co reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
Brown Brothers Harriman & Co sold 47,222 Myriad Genetics shares in Q1 2021, an estimated $934K.
Brown Brothers Harriman & Co first reported a position in Myriad Genetics in Q2 2014 and held it in 9 quarters.
Brown Brothers Harriman & Co's Myriad Genetics position peaked at $1.35M in Q3 2019.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2021, filed 13 May 2021.